Let us take a look at three biotech companies due to release their first-quarter financial results on May 12.
Investors have probably pretty much forgotten that Adaptive Biotechnologies (NASDAQ: ADPT) shares sank more than 40% earlier this year. Adaptive Biotechnologies announced first-quarter revenue of $20.9 million, a 65% jump from the $12.7 million reported in the same quarter of the previous year.
SEATTLE, April 27, 2020 -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive.
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
The U.S. death toll from the coronavirus that causes COVID-19 rose above 71,000 on Wednesday, as President Donald Trump appeared to back off his announcement that he would phase out the government task force created to manage the pandemic
Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced on Tuesday it has begun enrolling a virtual clinical study, ImmuneRACE, as part of a broader effort it has undertaken with Microsoft Corp. (Nasdaq: MSFT) to rapidly map and measure the immune response to the COVID-19 virus to inform improved diagnostics to fulfill the need for more reliable testing. The study calls for 1,000 participants in select U.S. metropolitan areas impacted by COVID-19. De-identified data will be made freely available to public health officials, academia and industry to help accelerate solutions to the pandemic. LabCorp (NYSE: LH), through its Covance drug development business, will manage the collection of blood samples and nose/throat swabs from participants in the comfort and safety of their own homes.
Ladies and gentlemen, thank you for standing by, and welcome to the Adaptive Biotechnologies first-quarter financial results conference call. Earlier today, Adaptive Biotechnologies released financial results for the first quarter ended March 31, 2020.
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
SEATTLE, May 12, 2020 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the.
The "ImmuneRace" study will genetically map the T-cells of 1,000 people who have been exposed to SARS-CoV-19.
Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will participate in the following investor virtual conferences. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities Virtual Healthcare Conference. Adaptive Biotechnologies’ management is scheduled to present on Wednesday, May 13th at 12:00 p.m. Pactific Time / 3:00 p.m. Eastern Time.
One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s recent headway in an early-stage coronavirus vaccine trial.
Shares of Adaptive Biotechnologies Corp. were up 7.5% in premarket trading on Wednesday. The company on Tuesday had announced a virtual clinical study with Microsoft Corp. aimed at better understanding the immune response in 1,000 people who have tested positive for COVID-19 or have been exposed to the virus. The study will utilize diagnostic tests made by Laboratory Corporation of America Holdings , who will send employees to the participants' homes to collect the samples, which will then be used to examine patients' T-cells. Adaptive previously announced plans to work on an antibody program with Amgen that aims to develop a therapy that can prevent or treat COVID-19. Adaptive's stock is up 10.3% since the start of the year, while the S&P 500 is down 11.2%.
Stable earnings from expansive fuel distribution assets are likely to have boosted Sunoco's (SUN) Q1 earnings.
Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.